Markers of oxidative stress in cyclosporine-treated and tacrolimus-treated children after liver transplantation.
Oxidative stress is presumed to have a major role in cyclosporine A (CsA)- and tacrolimus-induced tissue toxicity. The present study was performed to elucidate the degree of oxidative stress after liver transplantation in CsA- and tacrolimus-treated patients. Twenty-three patients (14 patients, CsA; 9 patients, tacrolimus) aged 2.5 to 18 years (mean, 9.8 years) who had undergone liver transplantation 1.5 to 12 years (mean, 5.4 years) before were studied. Eighteen healthy children aged 2 to 16.5 years (mean, 9.4 years) served as a control group. The following parameters were assessed: plasma lipoprotein levels; plasma carbonyl levels, as markers of oxidative damage to proteins; total plasma oxidizability, which evaluates plasma antioxidant capacity (lag phase) and lipoprotein susceptibility to oxidation; and plasma antioxidant capacity by cyclic voltammetry (CV), which measures antioxidant capacity stemming from hydrophilic low-molecular-weight antioxidant components. Carbonyl levels and rates of plasma oxidation did not differ between groups. The lag phase of plasma oxidation was significantly longer in CsA-treated children compared with tacrolimus-treated children or controls (mean, 54.4 +/- 4.8 [SE] v 40.2 +/- 2.2 v 46.5 +/- 2.8 minutes, respectively; P < 0.05). Antioxidant capacity, assessed by CV, did not differ among CsA-treated patients, tacrolimus-treated patients, and healthy controls. Plasma alpha-tocopherol and beta-carotene levels did not differ between CsA-treated and tacrolimus-treated patients. In children post-liver transplantation, oxidative damage assessed by markers of lipid and protein oxidation is not increased, and plasma antioxidant capacity is not diminished.
Granot
Esther
E
Department of Pediatrics, Hadassah University Hospital, Jerusalem, Israel. etgranot@md2.huji.ac.il
Elinav
Hila
H
Kohen
Ron
R
D000293:Adolescent; D000975:Antioxidants / Q000737:chemistry / Q000378:metabolism; D015415:Biomarkers; D001769:Blood / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood; D016031:Liver Transplantation; D008297:Male; D008970:Molecular Weight; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000502:physiology*; D011182:Postoperative Care; D011184:Postoperative Period; D016559:Tacrolimus / Q000627:therapeutic use*; D014801:Vitamin A / Q000097:blood; D014810:Vitamin E / Q000097:blood
D000975:Antioxidants; D015415:Biomarkers; D007166:Immunosuppressive Agents; D008074:Lipoproteins; D014801:Vitamin A; D014810:Vitamin E; D016572:Cyclosporine; D016559:Tacrolimus